Literature DB >> 32591937

Further evidence of low adherence to stimulant treatment in adult ADHD: an electronic medical record study examining timely renewal of a stimulant prescription.

Joseph Biederman1,2, Ronna Fried3,4, Maura DiSalvo3, K Yvonne Woodworth3, Itai Biederman3, Haley Driscoll3, Elizabeth Noyes3, Stephen V Faraone5,6, Roy H Perlis3,4,7.   

Abstract

RATIONALE: ADHD is a prevalent and morbid neurobiological disorder affecting up to 5% of adults. While stimulants have been documented to be safe and effective in adults with ADHD, uncertainties remain about adherence to these treatments.
OBJECTIVES: The main aim of this article was to evaluate contemporaneous rates and correlates of adherence to stimulants in adults with ADHD using data from electronic medical records from a large healthcare organization focusing on timely renewal of an initial prescription.
METHODS: Subjects were patients 18 to 44 years of age who had been prescribed a stimulant between January 1, 2015, and December 31, 2016. Prescription and sociodemographic data were extracted from the Partners HealthCare Research Patient Data Registry (RPDR). Our outcome metric was renewal of the index stimulant prescription defined as the first prescription recorded in the electronic record for the period under investigation.
RESULTS: We identified 2689 patients with an index prescription for a stimulant medication. Results showed that only 42% of patients renewed their prescriptions in a timely enough fashion to be considered consistently medicated.
CONCLUSIONS: Results indicate that adults with ADHD have a low rate of renewal of their initial stimulant prescription indicating poor patient engagement in their treatment for ADHD.

Entities:  

Keywords:  Adult ADHD; Attention-deficit/hyperactivity disorder; Electronic health records; Medication adherence; Non-renewal; Stimulants

Year:  2020        PMID: 32591937     DOI: 10.1007/s00213-020-05576-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  3 in total

1.  Oral Contraceptive and Menopausal Hormone Therapy Use and Risk of Pituitary Adenoma: Cohort and Case-Control Analyses.

Authors:  David J Cote; John L Kilgallon; Noah L A Nawabi; Hassan Y Dawood; Timothy R Smith; Ursula B Kaiser; Edward R Laws; JoAnn E Manson; Meir J Stampfer
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

2.  Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study.

Authors:  Jeff Schein; Ann Childress; Martin Cloutier; Urvi Desai; Andi Chin; Mark Simes; Annie Guerin; Julie Adams
Journal:  BMC Psychiatry       Date:  2022-06-03       Impact factor: 4.144

3.  Antidepressant use and risk of intubation or death in hospitalized patients with COVID-19: A retrospective cohort study of clinical effectiveness.

Authors:  Brian P Brennan; Jiana Schnabel; Harrison G Pope; James I Hudson
Journal:  Front Psychiatry       Date:  2022-09-15       Impact factor: 5.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.